Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

… compare the efficacy of erlotinib plus bevacizumab with erlotinib alone in patients with EGFR…
and erlotinib had improved progression-free survival compared with patients given erlotinib …

… with pemetrexed alone [17]. This intercalated therapy avoided the G1 arrest by erlotinib, thus
… In this meta-analysis, continuous erlotinib plus chemotherapy versus chemotherapy alone …

… erlotinib with a placebo for non–small-cell lung cancer demonstrated a survival benefit for
erlotinib… trial to investigate whether responsiveness to erlotinib and its impact on survival were …

… A study by the Cancer and Leukemia Group B found that the addition of carboplatin and … to
first‐line erlotinib was no better than erlotinib alone in never/light smokers with advanced lung …

… ) phase III trial, bevacizumab was added to erlotinib in patients with relapsed NSCLC.
Although PFS was improved with the combination compared with erlotinib alone (HR, 0.62; P < .…

… Bevacizumab and erlotinib target different tumour growth pathways with little overlap in their
… activity of erlotinib plus bevacizumab for recurrent or refractory non-small-cell lung cancer (…

… This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus
erlotinib compared with erlotinib alone in patients with pretreated, nonsmall-cell lung cancer (…

… EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression-free …
the combination of erlotinib and bevacizumab compared with erlotinib alone in patients with …

… erlotinib may enhance antitumor activity compared with either agent alone in non–small-cell
lung cancer (… plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC. …